Emergent BioSolutions Inc. — Director's Dealing 2019

Mar 1, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2019-02-26

Reporting Person: Havey Adam (EVP, Business Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-26	Common Stock	F	481	$61.01	Disposed	28772	Direct
2019-02-26	Common Stock	A	5081	—	Acquired	33853	Direct
2019-02-26	Common Stock	A	5081	$0.00	Acquired	38934	Direct
2019-02-27	Common Stock	F	409	$57.98	Disposed	38525	Direct
2019-02-28	Common Stock	F	812	$58.71	Disposed	37713	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-26	Employee Stock Option (Right to Buy)	$61.01	A	20321	Acquired	2026-02-25	Common Stock (20321)	Direct

Footnotes

F1: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated.

F2: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F3: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period.

F4: Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company.